Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Westermann

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
Cancer Letters|July 1, 2015
MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastomaAnneleen Beckers, Gert Van Peer, Daniel R Carter, et al.
Plos One|January 12, 2013
Focal DNA copy number changes in neuroblastoma target MYCN regulated genesCandy Kumps, Annelies Fieuw, Pieter Mestdagh, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Leukemia|November 5, 2022
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistanceAnna-Katharina Wirth, Lucas Wange, Sebastian Vosberg, et al.
Genome Biology|August 1, 2023
Effective methods for bulk RNA-seq deconvolution using scnRNA-seq transcriptomesFrancisco Avila Cobos, Mohammad Javad Najaf Panah, Jessica Epps, et al.
Blood|September 22, 2025
Telomere content and genomics of myeloid neoplasia by whole-genome sequencingLuca Guarnera, Adam Wahida, Carmelo Gurnari, et al.
Pharmacological Research|January 19, 2025
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacyLaura Grunewald, Lena Andersch, Konstantin Helmsauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2015
Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionAnton Henssen, Kristina Althoff, Andrea Odersky, et al.
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
International Journal of Cancer|April 12, 2022
A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsisUmar Khalid, Milena Simovic, Linda A Hammann, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
Cancer Letters|July 1, 2015
MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastomaAnneleen Beckers, Gert Van Peer, Daniel R Carter, et al.
Plos One|January 12, 2013
Focal DNA copy number changes in neuroblastoma target MYCN regulated genesCandy Kumps, Annelies Fieuw, Pieter Mestdagh, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Leukemia|November 5, 2022
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistanceAnna-Katharina Wirth, Lucas Wange, Sebastian Vosberg, et al.
Genome Biology|August 1, 2023
Effective methods for bulk RNA-seq deconvolution using scnRNA-seq transcriptomesFrancisco Avila Cobos, Mohammad Javad Najaf Panah, Jessica Epps, et al.
Blood|September 22, 2025
Telomere content and genomics of myeloid neoplasia by whole-genome sequencingLuca Guarnera, Adam Wahida, Carmelo Gurnari, et al.
Pharmacological Research|January 19, 2025
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacyLaura Grunewald, Lena Andersch, Konstantin Helmsauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2015
Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionAnton Henssen, Kristina Althoff, Andrea Odersky, et al.
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
International Journal of Cancer|April 12, 2022
A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsisUmar Khalid, Milena Simovic, Linda A Hammann, et al.
Pageof 14